Early Increase in Autoantibodies Against Human Oxidized Low-Density Lipoprotein in Hypertensive Patients After Blood Pressure Control

Early Increase in Autoantibodies Against Human Oxidized Low-Density Lipoprotein in Hypertensive Patients After Blood Pressure Control

Author Brandao, Sergio A. Autor UNIFESP Google Scholar
Izar, Maria C. Autor UNIFESP Google Scholar
Fischer, Simone M. Autor UNIFESP Google Scholar
Santos, Andreza O. Autor UNIFESP Google Scholar
Monteiro, Carlos M. Autor UNIFESP Google Scholar
Povoa, Rui M. Autor UNIFESP Google Scholar
Helfenstein, Tatiana Autor UNIFESP Google Scholar
Carvalho, Antonio C. Autor UNIFESP Google Scholar
Monteiro, Andrea M. Google Scholar
Ramos, Eduardo Google Scholar
Gidlund, Magnus Google Scholar
Figueiredo Neto, Antonio M. Google Scholar
Fonseca, Francisco A. Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
Abstract BACKGROUNDOxidized lipoproteins and antioxidized low-density lipoprotein (anti-oxLDL) antibodies (Abs) have been detected in plasma in response to blood pressure (BP) elevation, suggesting the participation of the adaptive immune system. Therefore, treatment of hypertension may act on the immune response by decreasing oxidation stimuli. However, this issue has not been addressed. Thus, we have here analyzed anti-oxLDL Abs in untreated (naive) hypertensive patients shortly after initiation of anti hypertensive therapeutic regimens.METHODSTiters of anti-oxLDL Abs were measured in subjects with recently diagnosed hypertension on stage 1 (n = 94), in primary prevention of coronary disease, with no other risk factors, and naive of anti hypertensive medication at entry. Subjects were randomly assigned to receive perindopril, hydrochlorothiazide (HCTZ), or indapamide (INDA) for 12 weeks, with additional perindopril if necessary to achieve BP control. Abs against copper-oxidized LDL were measured by enzyme-linked immunosorbent assay.RESULTSTwelve-week antihypertensive treatment reduced both office-based and 24-h ambulatory BP measurements (P < 0.0005). the decrease in BP was accompanied by reduction in thiobarbituric acid-reactive substances (TBARS) (P < 0.05), increase in anti-oxLDL Ab titers (P < 0.005), and improvement in flow-mediated dilation (FMD) (P < 0.0005), independently of treatment. Although BP was reduced, we observed favorable changes in anti-oxLDL titers and FMD.CONCLUSIONSWe observed that anti-oxLDL Ab titers increase after antihypertensive therapy in primary prevention when achieving BP targets. Our results are in agreement with the concept that propensity to oxidation is increased by essential hypertension and anti-oxLDL Abs may be protective and potential biomarkers for the follow-up of hypertension treatment.
Keywords angiotensin-converting enzyme inhibitor
antibodies
blood pressure
diuretic
hypertension
oxidized LDL
Language English
Sponsor Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
The National Institute of Science and Technology of Complex Fluids (INCT-FCx)
The National Institute of Science and Technology-Nanomaterials for Integrated Markers (INCT-IINAMI)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Date 2010-02-01
Published in American Journal of Hypertension. New York: Nature Publishing Group, v. 23, n. 2, p. 208-214, 2010.
ISSN 0895-7061 (Sherpa/Romeo, impact factor)
Publisher Nature Publishing Group
Extent 208-214
Origin http://dx.doi.org/10.1038/ajh.2009.214
Access rights Closed access
Type Article
Web of Science ID WOS:000273887100023
URI http://repositorio.unifesp.br/handle/11600/32238

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account